Revenue Performance: Total revenue for Q4 2024 was $22.5 billion, up 6.7% YoY, driven by a 10% increase in US sales, while international sales grew by 2.5% with a negative impact of 290 basis points from STELARA. Yearly sales reached $88.8 billion, marking a 5.9% increase.
Profitability: Net income for the quarter stood at $3.43 billion, translating to an EPS of $1.41 compared to $1.70 YoY—a decline attributed to increased R&D expenditures. Adjusted net income was $4.9 billion, resulting in an adjusted EPS of $2.04, down from $2.29 YoY due to $0.22 per share impact from acquired IPR&D expenses.
R&D Investment: Johnson & Johnson invested approximately 24% of total sales into R&D, indicative of its commitment to innovation within its pharmaceutical and MedTech divisions.
Cash Flow: The company generated $20 billion in free cash flow in FY2024, reflecting strong operational efficiency despite increased capital outlay.